Skip to main content

Table 2 Immunohistochemistry based molecular subtypes and pathological features for breast cancers diagnosed in Botswana between 2011 and 2015

From: Report of clinico-pathological features of breast cancer in HIV-infected and uninfected women in Botswana

  *ER/PR+/HER2- n (%) ER/PR+/HER2+ n (%) ER−/PR−/HER2 + HER2 enriched n (%) ER−/PR−/HER2-Triple Negative n (%)
  132 (62.6%) 19 (9.0%) 15 (7.1%) 45 (21.3%)
Histologic grade
 Grade 1 33 (25.0) 5 (26.3) 1 (6.7) 2 (4.4)
 Grade 2 59 (44.7) 10 (52.6) 8 (53.3) 23 (51.1)
 Grade 3 21 (15.9) 3 (15.8) 3 (20.0) 13 (28.8)
 Not specified/missing 19 (14.4) 1 (5.3) 3 (20.0) 7 (15.5)
Age
  < 50 years 50 (37.8) 10 (52.6) 5 (33.3) 21 (46.7)
  ≥ 50 years 64 (48.5) 6 (31.6) 7 (46.7) 19 (42.2)
 Age not specified/missing 18 (13.6) 3 (15.8) 3 (20.0) 5 (11.1)
Stage
 Stage I and Stage II 5 (29.4) 0 (0.0) 0 (0.0) 2 (28.6)
 Stage III 12 (70.6) 1 (100.0) 3 (100.0) 5 (71.4)
  1. *ER/PR+/HER2-: ER+ or PR+ or both, and HER2-
  2. ER/PR+/HER2+: ER or PR+ or both, and HER2+
  3. ER−/PR−/HER2+: ER – and PR- and HER2+
  4. ER−/PR−/HER2-: ER- ad PR- and HER2-